Low Levels of Hepatocyte‐Specific Methylation in Cell‐Free DNA Are a Strong Negative Predictor for Acute T Cell–Mediated Rejection Requiring Treatment Following Liver Transplantation

Daniel R. A. Cox, Nicholas Low, Su Kah Goh, Eunice Lee, Angela Vago, Louise Jackett, Julie Lokan, Sabine Braat, Robert Jones, Adam Testro, Alexander Dobrovic, Vijayaragavan Muralidharan – 15 December 2021 – Graft‐derived cell‐free DNA (gdcfDNA) quantification is a promising, minimally invasive tool for detecting acute T cell–mediated rejection (ATCMR) following liver transplantation (LT). We investigated the utility of measuring hepatocyte‐specific methylation in cfDNA (HS‐cfDNA) to quantify gdcfDNA, examining its accuracy in detecting ATCMR in a prospective, cross‐sectional study.

Adverse Effects of Anti‐Covid‐19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes

Atousa Khalatbari, Zahra Aghazadeh, Cheng Ji – 14 December 2021 – During the pandemic, dexamethasone (DEX), remdesivir (RDV), hydroxychloroquine (HCQ), thapsigargin (TG), camostat mesylate (CaM), and pralatrexate were repurposed drugs for coronavirus disease 2019 (COVID‐19). However, the side effects on the liver associated with the anti‐COVID therapies are unknown. Cellular stresses by these drugs at 0‐30 μM were studied using HepG2, Huh7, and/or primary human hepatocytes.

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.

MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells

Yong Chen, Xiangwei Hua, Bingyuan Huang, Stella Karsten, Zhengrui You, Bo Li, You Li, Yikang Li, Jubo Liang, Jun Zhang, Yiran Wei, Ruiling Chen, Zhuwan Lyu, Xiao Xiao, Min Lian, Jue Wei, Jingyuan Fang, Qi Miao, Qixia Wang, Ulrika Warpman Berglung, Ruqi Tang, Thomas Helleday, Xiong Ma – 9 December 2021 – Autoimmune hepatitis (AIH) is an inflammatory liver disease driven by the hyperactivation of various intrahepatic antigen‐specific T cells due to a breach of immune tolerance.

NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH

Jonathan G. Stine, Ian R. Schreibman, Alison J. Faust, Jessica Dahmus, Benjamin Stern, Christopher Soriano, Gloriany Rivas, Breianna Hummer, Scot R. Kimball, Nate R. Geyer, Vernon M. Chinchilli, Rohit Loomba, Kathryn Schmitz, Christopher Sciamanna – 9 December 2021

Subscribe to